1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Imago Biosciences is developing treatments for patients with life-threatening diseases of the bone marrow. Lysine-specific demethylase 1 (LSD1) is a protein that plays a key role in the behavior of malignant blood cells by influencing which genes are expressed. Imago focuses on studying the activity of LSD1, which they believe offers the greatest chance of treating bone marrow diseases since LSD1 plays a unique role in each step of blood cell formation. This includes the discovery and development of identifying small molecule inhibitors and degraders of LSD1. Imago’s lead product, bomedemstat, is an orally available inhibitor of LSD1 that is currently being tested in clinical trials for patients with myeloproliferative neoplasms. Imago BioSciences is a clinical-stage biopharmaceutical company developing novel small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. The company's lead product candidate, bomedemstat, is an orally available, small molecule inhibitor of LSD1. Bomedemstat is currently in clinical trials for the treatment of essential thrombocythemia (ET) and myelofibrosis (MF). On November 21, 2022, Merck acquired Imago BioSciences for $1.35 billion.

<p>Imago Biosciences is developing treatments for patients with life-threatening diseases of the bone marrow. Lysine-specific demethylase 1 (LSD1) is a protein that plays a key role in the behavior of malignant blood cells by influencing which genes are expressed. Imago focuses on studying the activity of LSD1, which they believe offers the greatest chance of treating bone marrow diseases since LSD1 plays a unique role in each step of blood cell formation. This includes the discovery and development of identifying small molecule inhibitors and degraders of LSD1. Imago’s lead product, bomedemstat, is an orally available inhibitor of LSD1 that is currently being tested in clinical trials for patients with myeloproliferative neoplasms.</p>


Find a biotech startup job.